Drug intelligence / Profile preview

AND-383

Development stage: Preclinical
Lead developer: Neuropathix
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

AND-383 is a small-molecule drug with neuroprotective and anticonvulsant properties. It was acquired by Neuropathix, Inc. from Advanced Neural Dynamics, Inc. and Fox Chase Chemical Diversity Center, Inc. on December 18, 2020. The acquisition aimed to expand Neuropathix's pipeline, particularly for refractory epilepsy and neuropathic pain, and integrate preclinically validated compounds into its clinical development strategy.

Beyond the preview

Go deeper on AND-383.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AND-383.

Explore the full profile